NKL 22
NKL 22 (compound 4b) is a potent and selective inhibitor of histone deacetylases (HDAC), with an IC50 of 199 and 69 nM for HDAC1 and HDAC3, respectively. NKL 22 exhibits selectivity over HDAC2/4/5/7/8 (IC50≥1.59 μM) . NKL 22 ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice[1][2][3].
Product Specifications
CAS Number
537034-15-4
UNSPSC
12352005
Hazard Statement
H302
Target
HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/NKL-22.html
Purity
97.26
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=CC=C1N)CCCCCC(NC2=CC=CC=C2)=O
Molecular Formula
C19H23N3O2
Molecular Weight
325.40
Precautions
H302
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC1; HDAC2; HDAC3; HDAC8
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD45RA (111-1C5), CF568 conjugate, 0.1mg/mL
